Name
104: SGLT2 Inhibitors for Prevention of Chronic Kidney Disease and Heart Failure: Implications for Older Adults
Date & Time
Friday, March 22, 2024, 1:20 PM - 2:20 PM
Speakers
Description
Individuals with chronic kidney disease (CKD) are at an increased risk of heart failure; conversely, kidney function decline is common in individuals with heart failure (HF). Sodium–glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression and hospitalization for heart failure, both in patients with CKD and in patients with HF. This session will address the beneficial effects of SGLT2 inhibitors for the treatment of CKD and HF in older adults.
Session Type
General
Contact Hours
1.00
Pharmacology Contact Hours
1.00